{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:37:27Z","timestamp":1767832647196,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","award":["201201140"],"award-info":[{"award-number":["201201140"]}],"id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Infection by Hepatitis C virus (HCV) can lead to liver cirrhosis\/hepatocellular carcinoma and remains a major cause of serious disease morbidity and mortality worldwide. However, current treatment regimens remain inaccessible to most patients, particularly in developing countries, and, therefore, the development of a novel vaccine capable of protecting subjects from chronic infection by HCV could greatly reduce the rates of HCV infection, subsequent liver pathogenesis, and in some cases death. Herein, we evaluated two different semi-synthetic archaeosome formulations as an adjuvant to the E1\/E2 HCV envelope protein in a murine model and compared antigen-specific humoral (levels of anti-E1\/E2 IgG and HCV pseudoparticle neutralization) and cellular responses (numbers of antigen-specific cytokine-producing T cells) to those generated with adjuvant formulations composed of mimetics of commercial adjuvants including a squalene oil-in-water emulsion, aluminum hydroxide\/monophosphoryl lipid A (MPLA) and liposome\/MPLA\/QS-21. In addition, we measured the longevity of these responses, tracking humoral, and cellular responses up to 6 months following vaccination. Overall, we show that the strength and longevity of anti-HCV responses can be influenced by adjuvant selection. In particular, a simple admixed sulfated S-lactosylarchaeol (SLA) archaeosome formulation generated strong levels of HCV neutralizing antibodies and polyfunctional antigen-specific CD4 T cells producing multiple cytokines such as IFN-\u03b3, TNF-\u03b1, and IL-2. While liposome\/MPLA\/QS-21 as adjuvant generated superior cellular responses, the SLA E1\/E2 admixed formulation was superior or equivalent to the other tested formulations in all immune parameters tested.<\/jats:p>","DOI":"10.3390\/vaccines7040204","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T04:30:35Z","timestamp":1575433835000},"page":"204","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins"],"prefix":"10.3390","volume":"7","author":[{"given":"Bassel","family":"Akache","sequence":"first","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Deschatelets","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renu","family":"Dudani","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7547-8493","authenticated-orcid":false,"given":"Felicity C.","family":"Stark","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Jia","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Landi","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L. M.","family":"Law","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Logan","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Hockman","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juthika","family":"Kundu","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Lorne","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Houghton","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Virology, Department of Medical Microbiology &amp; Immunology, University of Alberta, 6-010 Katz Group-Rexall Centre for Health Research, Edmonton, AB T6G 2E1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-1363","authenticated-orcid":false,"given":"Michael J.","family":"McCluskie","sequence":"additional","affiliation":[{"name":"National Research Council Canada, Human Health Therapeutics, 1200 Montreal Rd, Ottawa, ON K1T 0H1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"key":"ref_1","unstructured":"(2019, July 09). World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1073\/pnas.91.4.1294","article-title":"Vaccination of chimpanzees against infection by the hepatitis C virus","volume":"91","author":"Choo","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Law, J.L., Chen, C., Wong, J., Hockman, D., Santer, D.M., Frey, S.E., Belshe, R.B., Wakita, T., Bukh, J., and Jones, C.T. (2013). A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059776"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nature04081","article-title":"Prospects for a vaccine against the hepatitis C virus","volume":"436","author":"Houghton","year":"2005","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-065X.2010.00977.x","article-title":"Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses","volume":"239","author":"Houghton","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Akache, B., Stark, F.C., Jia, Y., Deschatelets, L., Dudani, R., Harrison, B.A., Agbayani, G., Williams, D., Jamshidi, M.P., and Krishnan, L. (2018). Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0208067"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1016\/S0264-410X(01)00041-X","article-title":"Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes","volume":"19","author":"Conlan","year":"2001","journal-title":"Vaccine"},{"key":"ref_12","first-page":"578432","article-title":"Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses","volume":"2010","author":"Krishnan","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1016\/j.vaccine.2017.10.072","article-title":"Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes","volume":"35","author":"Landi","year":"2017","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/21645515.2017.1423154","article-title":"Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants","volume":"14","author":"Akache","year":"2018","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4049\/jimmunol.173.1.566","article-title":"Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing","volume":"173","author":"Gurnani","year":"2004","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.4049\/jimmunol.178.4.2396","article-title":"Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2","volume":"178","author":"Krishnan","year":"2007","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Stark, F.C., McCluskie, M.J., and Krishnan, L. (2016). Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8(+) T Cells that Protect Against Subcutaneous B16-OVA Melanoma. Vaccines, 4.","DOI":"10.3390\/vaccines4040044"},{"key":"ref_18","unstructured":"Whitfield, D.M., Sprott, G.D., and Krishnan, L. (2016). Sulfated-Glycolipids as Adjuvants for Vaccines. (WO 2016\/004512 A1), U.S. Patent Application."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1080\/21645515.2017.1316912","article-title":"Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity","volume":"13","author":"McCluskie","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2019.02.041","article-title":"A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations","volume":"561","author":"Jia","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/IAI.68.1.54-63.2000","article-title":"Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional liposomes and alum","volume":"68","author":"Krishnan","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"513231","DOI":"10.1155\/2012\/513231","article-title":"Synthetic archaeosome vaccines containing triglycosylarchaeols can provide additive and long-lasting immune responses that are enhanced by archaetidylserine","volume":"2012","author":"Sprott","year":"2012","journal-title":"Archaea"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine Adjuvants: From 1920 to 2015 and Beyond","volume":"3","author":"Preiss","year":"2015","journal-title":"Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Garcon","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028018758431","article-title":"Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine","volume":"52","author":"James","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01552-16","DOI":"10.1128\/JVI.01552-16","article-title":"Native Folding of a Recombinant gpE1\/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG","volume":"91","author":"Logan","year":"2017","journal-title":"J. Virol."},{"key":"ref_27","unstructured":"Vandepapeliere, P. (2011). Vaccine Compositions Comprising a Saponin Adjuvant. (US 2011\/0206758 A1), U.S. Patent Application."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/acsinfecdis.6b00110","article-title":"Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets","volume":"2","author":"Freedman","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/infdis\/jir399","article-title":"Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains","volume":"204","author":"Stamataki","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2019.07.010","article-title":"Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization","volume":"37","author":"Stark","year":"2019","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: Helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1128\/JVI.02743-07","article-title":"Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Boyd, A., Almeida, J.R., Darrah, P.A., Sauce, D., Seder, R.A., Appay, V., Gorochov, G., and Larsen, M. (2015). Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138395"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2017.00197","article-title":"Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4(+) T Cells","volume":"8","author":"Muraro","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/204\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:39:43Z","timestamp":1760189983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/4\/204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["vaccines7040204"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7040204","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}